Frank Fedele, MD
Interventional Cardiology · Fayetteville, NCNPI 1972587996
Payments from drug & device makers
What this record shows
This record is dominated by other: $30,443 of the $35,966 with a category attached, or 84.6%. Angiodynamics, Inc. accounts for 93.8% of it on its own, with 31 other manufacturers making up the rest.
Across 144 payments — averaging $249.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$34K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$397
- Amgen$170
- Johnson & Johnson$161
- Boehringer Ingelheim$147
- Astellas Pharma US Inc$136
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,3236%
- Education$3,2009%
- Other$30,44385%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 16 | $33,740 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $397 |
| Amgen | 11 | $170 |
| Johnson & Johnson | 11 | $161 |
| Boehringer Ingelheim | 8 | $147 |
| Astellas Pharma US Inc | 7 | $136 |
| Abiomed | 5 | $125 |
| Edwards Lifesciences | 2 | $120 |
| Actelion Pharmaceuticals US, Inc. | 5 | $91 |
| Boston Scientific | 4 | $88 |
| AstraZeneca | 6 | $87 |
| Novartis | 5 | $66 |
| Merck | 4 | $55 |
| Baxter Healthcare | 3 | $55 |
| Cardiovascular Systems Inc. | 2 | $52 |
| Organogenesis Inc. | 1 | $47 |
| Kestra Medical Technology Services, Inc. | 2 | $45 |
| Elutia, Inc. | 3 | $44 |
| Medtronic | 2 | $44 |
| Amarin Pharma, Inc. | 2 | $40 |
| Teleflex LLC | 2 | $33 |
| Pfizer | 2 | $31 |
| Vital Connect, Inc | 1 | $28 |
| Abbott | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Terumo Medical Corporation | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,966 in reported general payments places this provider in the 80th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $59,030 |
| EntrestoSacubitril/Valsartan | 28 | $24,772 |
| BrilintaTicagrelor | 28 | $15,614 |
| FarxigaDapagliflozin Propanediol | 12 | $9,536 |
| Metoprolol Succinate | 123 | $1,444 |
| Nifedipine ErNifedipine | 24 | $855 |
| Atorvastatin Calcium | 67 | $580 |
| ClopidogrelClopidogrel Bisulfate | 55 | $515 |
| Rosuvastatin Calcium | 36 | $444 |
| Ezetimibe | 13 | $439 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $394 |
| Amlodipine Besylate | 57 | $370 |
| Lisinopril | 47 | $362 |
| Potassium Chloride | 23 | $362 |
| Nitroglycerin | 23 | $327 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $59,03072 claims |
| AstraZenecaBrilinta, Farxiga | $87 | $25,15040 claims |
| NovartisEntresto | $66 | $24,77228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Fayetteville
- Suriya JayawardenaFayetteville$56K
- Matthew DakaFayetteville$16K
- Michael MillerFayetteville$10K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.